课题基金 / 基金详情

R-HU-EPO FOR ANEMIA OF PREMATURITY

R-HU-EPO FOR ANEMIA OF PREMATURITY
R-HU-EPO 治疗早产儿贫血
批准号：
6280850
负责人：
RODERIC H PHIBBS
金额：
$2.39万
依托单位：
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
依托单位国家：
美国
项目类别：
财政年份：
1997
资助国家：
美国
项目状态：
已结题
起止时间：
1997-12-01 至 1998-11-30
来源：
https://reporter.nih.gov/project-details/6280850
关键词：
anemia blood disorder chemotherapy clinical research clinical trial phase I erythropoietin human subject human therapy evaluation premature infant human recombinant proteins

项目摘要

项目成果

RODERIC H PHIBBS的其他基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Anemia of prematurity is the major cause for red blood cell transfusions in the neonatal intensive care unit. Most very low birthweight infants receive multiple transfusions. Inadequate production of EPO in response to anemia is one of the factors contributing to amenia of prematurity. Trials of r-Hu-EPO given to stable, older infants have shown it to be a safe and effective treatment for anemia of prematurity. This study is undertaken to determine whether very early treatment of extremely premature infants with will have a greater effect in reducing transfusions than the current practice of beginning treatment at 2-3 weeks after birth. Status: This multi-centered study may not be implemented at UCSF. Activities undertaken to date include r-Hu-EPO related presentations and publications.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
THROMBOPOIETIN IN NORMAL AND THROMBOCYTOPENIC NEWBORN INFANTS
THROMBOPOIETIN IN NORMAL AND THROMBOCYTOPENIC NEWBORN INFANTS
THROMBOPOIETIN IN NEONATAL THROMBOCYTOPENIA
THROMBOPOIETIN IN NEONATAL THROMBOCYTOPENIA